dr. corey langer discusses afatinib in egfr-positive nsclc
Published 11 years ago • 187 plays • Length 0:45Download video MP4
Download video MP3
Similar videos
-
1:30
dr. langer on afatinib for advanced non-small cell lung cancer
-
1:07
dr. corey langer discusses erlotinib in advanced non-small cell lung cancer
-
2:03
dr. corey langer discusses treating locally advanced non-small cell lung cancer
-
1:54
dr. langer discusses the impact of targeted therapy in nsclc
-
0:58
the activity of afatinib in lung cancer
-
4:09
frontline afatinib in egfr-mutant nsclc
-
2:19
dr. langer discusses the treatment of patients with early stage lung cancer
-
2:18
dr. corey langer discusses alk inhibitors
-
7:15
2013 oncprac summit: corey langer on managing nsclc
-
3:17
corey j. langer, md: use of tki therapy in patients with egrf exon 19 deletion nsclc
-
6:41
egfr-positive nsclc: treatment at progression
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
1:25
dr. bunn discusses afatinib in lung cancer
-
6:14
third-generation egfr inhibitors in nsclc
-
6:46
selecting a first-line egfr inhibitor in nsclc
-
1:47
dr. langer on the current state of immunotherapy in advanced nsclc
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
2:36
dr. corey langer squamous cell lung cancer - jan. 24, 2017
-
2:28
dr. langer on treating patients with early stage lung cancer